If you've been taking glutathione for a few months and your skin or energy hasn't changed much, the supplement probably isn't the problem
A rare lethal fatty acid oxidation defect
This strategy has been exploited in the long-acting GLP-1RA semaglutide (Novo Nordisk), for instance, which was approved for treatment of T2DM in 2017, and for treatment of obesity in 2021, and has since then become the most prescribed GLP-1RA 92
What limited research shows Clinical research on tirzepatide for weight loss has focused almost entirely on brand-name formulations, not compounded versions
However, the choice is yours
Although the oral form is slightly less effective, doctors say it's opening the market to many more potential customers